Apple's Watch Ban Temporarily Lifted, US Appeal Courts Pause ITC Ruling

Apple Inc. has won a temporary reprieve, allowing the resumption of sales for its flagship smartwatches. This victory comes after a US appeals court paused an import ban imposed by the US International Trade Commission (ITC) in a patent dispute centred around Apple's medical monitoring technology.

The battle unfolded when the ITC ruled that Apple had violated patents owned by Masimo, a medical technology company based in Irvine, California. The decision had temporarily halted Apple Watch sales and left both tech giants on the brink of a high-stakes legal showdown.

Apple swiftly responded by filing an emergency request with the US Court of Appeals for the Federal Circuit, seeking a stay on the ITC's order. The court's decision, though temporary, marks a significant development in a dispute that could potentially cost millions of dollars to either company.

Masimo's shares closed 4.6% lower at $115.11 per share after the court's decision, while Apple's shares remained flat at $193.15 per share. The financial implications of a final decision loom large, but analysts suggest that the adverse publicity generated by the lawsuit might overshadow any monetary losses for Apple.

"We are thrilled to return the full Apple Watch lineup to customers in time for the new year," Apple stated. "Apple Watch Series 9 and Apple Watch Ultra 2, including the blood oxygen feature, will become available for purchase again in the United States at Apple Stores starting today and from apple.com tomorrow by 12 pm PT."

While Apple celebrates this temporary victory, Masimo chose to remain silent on the court's decision. The ITC's initial ban targeted Apple Watches featuring technology for reading blood-oxygen levels, a capability introduced with Apple's Series 6 model in 2020.

Masimo's allegations against Apple involve claims of employee poaching, theft of pulse oximetry technology, and its subsequent integration into Apple Watches. Apple, in turn, countersued, dismissing Masimo's legal actions as an attempt to eliminate competition for its own smartwatches.

Stuart Cole, Chief Macro Economist at Equiti Capital, sheds light on the situation, stating, "Apple can easily develop their own blood monitoring software; it is just a matter of time. The software development costs are not something that will be too concerning for a company as wealthy as Apple." Cole emphasizes that Apple's focus in this legal battle is not just on the specific blood oxygen monitoring software but also on safeguarding its reputation in the emerging health-wearable products market.

The court's four-paragraph ruling provides a temporary halt to the ban while it considers Apple's request for a longer-term pause during the appeals process. The ITC has until January 10 to respond to Apple's request. Notably, US President Joe Biden's administration declined to veto the ban, allowing it to take effect, but Apple's legal and technical manoeuvres are in full swing.

Apple has informed the court that the US Customs and Border Protection is evaluating redesigned versions of its watches to determine if they infringe Masimo's patents and can be imported. The customs agency is expected to make a decision by January 12. Apple had previously halted sales of the affected devices on its website and retail locations in the US, although they remained available through various retailers like Amazon, Best Buy, Costco, and Walmart.

The ban specifically targeted Apple Watches with blood oxygen monitoring technology, sparing the less-expensive Apple Watch SE, which lacks a pulse oximeter. Previous models of the Apple Watch were also unaffected by the ban.

The legal battle between Apple and Masimo reached a crescendo with a mistrial in a California federal court in May. Despite the ongoing legal challenges, Apple's wearables, home, and accessory business, including the Apple Watch, AirPods earbuds, and other products, generated $8.28 billion in revenue during the third quarter of 2023, according to a company report.

As the legal tech tango continues, industry observers keenly await the final decision that could shape the fate of Apple's smartwatches as well as the trajectory of innovation in the fiercely competitive wearables market.

*Inputs from Reuters*